Intra-Cellular Therapies Overview
Intra-Cellular Therapies (ITCI) has a ROE of -6.5%, below the Healthcare sector average of 22.01%.
Get informed when a big investor buys or sells
+ Follow-6.50%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for ITCI is -6.5%. That is below the Healthcare sector average of 22.01%. Investors often review this figure alongside Intra-Cellular Therapies's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, ITCI currently prints -6.5% for ROE, while the sector average sits near 22.01%. That is roughly 129.5% below the sector mean. Large gaps often invite a closer look at Intra-Cellular Therapies's growth, margins, and balance sheet.
Return on Equity shows how effectively Intra-Cellular Therapies converts resources into returns. At -6.5%, ITCI may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting ITCI's ROE (-6.5%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Intra-Cellular Therapies's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
